{"nctId":"NCT02564211","briefTitle":"Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)","startDateStruct":{"date":"2015-10-26","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":77,"armGroups":[{"label":"Ipragliflozin","type":"EXPERIMENTAL","interventionNames":["Drug: Ipragliflozin","Drug: Sitagliptin"]}],"interventions":[{"name":"Ipragliflozin","otherNames":[]},{"name":"Sitagliptin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has Type 2 diabetes mellitus\n* Has inadequate glycemic control on diet/exercise therapy and sitagliptin monotherapy\n* Hemoglobin A1C (HbA1c) ≥7.0% and ≤10.0% before study participation\n\nExclusion Criteria:\n\n* History of type 1 diabetes mellitus or a history of ketoacidosis\n* History of any of the following medications: Thiazolidinediones (TZD) and/or insulin within 12 weeks prior to study participation, sodium glucose cotransporter 2 (SGLT2) inhibitors anytime\n* Currently has a urinary tract infection or genital infection with subjective symptom","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Experienced at Least 1 Adverse Event (AE)","description":"An AE was any unfavorable or unintended sign, symptom, or disease, and a causal relationship to the relevant investigational product is not considered. An AE could therefore be any unfavorable and unintended sign, including results from laboratory assessments, physical examination, electrocardiograms, and vital sign assessments. The percentage of participants that had AE was recorded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Had Study Drug Discontinued Due to an AE","description":"The percentage of participants who had study treatment stopped due to an AE regardless if they completed study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c","description":"Participants had HbA1c levels determined at baseline and at Week 52. HbA1c is reported as a percentage. A negative number reflects a decrease in percentage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.80","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":77},"commonTop":["Nasopharyngitis","Back pain","Pollakiuria","Thirst","Constipation"]}}}